These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32303191)

  • 1. Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews.
    Zhao Q; Shen J; Lu J; Jiang Q; Wang Y
    BMC Cardiovasc Disord; 2020 Apr; 20(1):179. PubMed ID: 32303191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
    Musini VM; Lawrence KA; Fortin PM; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007066. PubMed ID: 28379619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
    Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
    Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.
    Gradman AH; Weir MR; Wright M; Bush CA; Keefe DL
    J Hum Hypertens; 2010 Nov; 24(11):721-9. PubMed ID: 20200550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.
    Angeli F; Reboldi G; Mazzotta G; Poltronieri C; Garofoli M; Ramundo E; Biadetti A; Verdecchia P
    Curr Drug Saf; 2012 Feb; 7(1):76-85. PubMed ID: 22663961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy, safety and tolerability of aliskiren monotherapy: a protocol for an umbrella review.
    Zhao Q; Shen J; Lu J; Li F; Jiang Q; Wang Y
    BMJ Open; 2020 Jan; 10(1):e033448. PubMed ID: 31969367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
    Musini VM; Fortin PM; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2008 Oct; (4):CD007066. PubMed ID: 18843743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety profile of aliskiren: practical implications for clinicians.
    Angeli F; Reboldi G; Poltronieri C; Angeli E; De Filippo V; Crocetti A; Bartolini C; D'Ambrosio C; Verdecchia P
    Curr Drug Saf; 2014; 9(2):106-17. PubMed ID: 24517108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy.
    Takenaka T; Nobe K; Okayama M; Kojima E; Nodaira Y; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
    Clin Exp Hypertens; 2012; 34(4):243-8. PubMed ID: 22559034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.
    Bjerre HL; Christensen JB; Buus NH; Simonsen U; Su J
    J Hum Hypertens; 2019 Nov; 33(11):795-806. PubMed ID: 30631130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct renin inhibition: focus on aliskiren.
    Pool JL
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):21-33. PubMed ID: 17970614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy.
    Tocci G; Aimo G; Caputo D; De Matteis C; Di Napoli T; Granatelli A; Lentini P; Magagna A; Matarrese AA; Perona D; Villa G; Volpe M;
    High Blood Press Cardiovasc Prev; 2012 Jun; 19(2):73-83. PubMed ID: 22867093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
    Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
    N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.
    Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
    J Renin Angiotensin Aldosterone Syst; 2011 Jun; 12(2):102-12. PubMed ID: 21059822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
    Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
    Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren in patients with diabetes: a systematic review.
    Rizos EC; Agouridis AP; Elisaf MS
    Curr Vasc Pharmacol; 2012 Mar; 10(2):140-6. PubMed ID: 22239623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.